Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSI) Net Cash Flow (2022 - 2025)

TriSalus Life Sciences (TLSI) has 4 years of Net Cash Flow data on record, last reported at -$2.2 million in Q4 2025.

  • For Q4 2025, Net Cash Flow rose 18.64% year-over-year to -$2.2 million; the TTM value through Dec 2025 reached $11.9 million, up 466.36%, while the annual FY2025 figure was $11.9 million, 466.36% up from the prior year.
  • Net Cash Flow reached -$2.2 million in Q4 2025 per TLSI's latest filing, up from -$3.8 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $17.5 million in Q3 2023 and bottomed at -$17.8 million in Q3 2022.
  • Average Net Cash Flow over 4 years is -$594500.0, with a median of -$2.7 million recorded in 2022.
  • Peak YoY movement for Net Cash Flow: crashed 15785.95% in 2023, then surged 536.99% in 2024.
  • A 4-year view of Net Cash Flow shows it stood at -$2.7 million in 2022, then plummeted by 255.5% to -$9.5 million in 2023, then surged by 70.93% to -$2.8 million in 2024, then increased by 18.64% to -$2.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Cash Flow were -$2.2 million in Q4 2025, -$3.8 million in Q3 2025, and $13.5 million in Q2 2025.